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sensitivity (0.94), speciﬁcity (0.96), PPV (0.978) and Youden’s index
(0.9). The surface protein expression of KIR3DL1, measured by ﬂow
cytometry (DX9) correlated well with the relative expression by Q-
PCR (r  .418; P  .027). We then applied the Q-PCR assay to 3
discrete subpopulations of blood NK cells sorted using a cocktail of 3
antibodies (GL183, EB6 and DX9) that recognize 6 KIR genes
(CD56bright, CD56dimKIRAb, and CD56dimKIRAb-). Com-
pared to the combined CD56dimcell populations, CD56brightNK
cells (thought to be developmentally immature) had lower levels of
gene expression for all KIR except 2DL4. Interestingly, the
CD56dimKIRAb cells expressed higher amounts of the 7 KIR
genes not included in the sorting cocktail than did the
CD56dimKIR cells (median ratio of 5.05; P  .0001). The
CD56dimKIRAb cells had low gene expression for all KIR.
KIR2DL4, which is regulated differently than the other KIR, was the
most highly expressed gene in the CD56dimKIRAbcells. Addition-
ally, CD56dimKIRAb cells express a compensatory rise in NKG2A
(which precedes KIR expression duringNK development) when com-
pared to a CD56dimKIRAb population using ﬂow cytometry
(75.3 12.5% vs 32.0 6.6%; P .038). This demonstrates that the
mature, circulating population of CD56dim NK cells is comprised of
KIR-expressing and KIR-negative populations. Together, these re-
sults suggest that KIR expression may be a marker of maturation with
KIR acquisition under a common locus control mechanism. It also
identiﬁes a large population of mature NK cells lacking inhibitory
KIR that have the potential to become alloreactive if other inhibitory
interactions can be evaded.
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CMV, Adenovirus (Ad), and EBV are major viral pathogens post
allogeneic SCT. Adoptive immunotherapy with donor-derived Cy-
totoxic T Lymphocytes (CTL) can prevent the clinical manifesta-
tions of EBV and CMV. We have extended these studies by
generating CTL from donor PBMC that can restore cellular im-
munity to CMV, EBV, and Ad simultaneously. Our protocol uti-
lizes stimulation with mononuclear cells transduced with a recom-
binant Ad type 5 vector pseudotyped with a type 35 ﬁber carrying
a transgene for the CMV antigen pp65, followed by 2 stimulations
with EBV-lymphoblastoid cell lines transduced with the same
vector. After 3 stimulations, 10 CTL cultures contained a mean of
83% (range 8.4–98.99%) CD8ve and a mean of 19.6% (range
2.2–91.6%) CD4ve cells. In Cr release /or IFNELISPOT
assays, all CTL lines showed speciﬁc activity against CMV and
EBV targets; 9/10 lines also showed speciﬁcity against Ad targets.
Further, using MHC-peptide multimers we have demonstrated the
simultaneous presence of CD8ve cells recognizing peptide
epitopes from CMV pp65 (range 2.32–21%) and Ad hexon (1.07–
8.08%) in the CTL cultures. We have treated 6 patients in this
phase I CMV prophylaxis study, 3 on DL1(1  107/m2) and 3 on
DL2(5 107/m2). Patients received one infusion of virus-speciﬁc
CTL from 54–120 days post SCT. We observed up to a 28-fold
increase in CMV pentamer ve CD8 T cells post CTL. At last
follow-up (12–40 wks post CTL infusion) all patients are CMV
and EBV neg. Two patients were transiently ve for CMV by
PCR 4–9 weeks post CTL but both were neg 7 days later without
anti-viral therapy, with a corresponding rise in CMV-speciﬁc CTL
detected in the peripheral blood. Two patients were culture ve
for Ad in stool/ blood pre-CTL therapy. One of these patients
was infected with Ad species from subgroups A, C, and D and the
other with group C alone. In both patients, we observed a 2-log
reduction of adenoviral load within 2–3 weeks post CTL infusion
at which time their symptoms (fever, loose stools) resolved. In
summary, we can efﬁciently generate multi-virus speciﬁc CTL.
Infusion of these cells included virus-speciﬁc CD8ve T cells in
the peripheral blood post CTL infusion. Further, reduction in Ad
load in stool/blood suggests efﬁcacy of Ad-speciﬁc CTL in vivo.
However, expansion of virus-speciﬁc CTL in vivo may require
presence of antigen. We will complete this prophylaxis study and
then proceed to using virus-speciﬁc CTL for the treatment of
CMV and Ad disease post SCT.
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Regulatory T cells (Treg) reduce the incidence and severity of
acute graft-versus-host disease (GvHD) in murine models of ma-
jor-MHC mismatched hematopoietic cell transplantation (HCT).
It is unclear whether the effect of Treg on effector T cells is a
selective or nonselective process or if Treg regulate the process of
intrathymic and peripheral T cell maturation and selection follow-
ing HCT. The current study assessed the impact of Treg on the
quantitative and functional lymphoid reconstitution after HCT.
Treg from FVB/N (H2q) mice were co-transplanted into lethally
irradiated Balb/c (H2d) host along with FVB/N T cell depleted
bone marrow cells and CD4/CD8 cells, the latter to induce
GvHD. At days 14 and 40 post-transplantation, total lymphoid
reconstitution was delayed in the GvHD group and enhanced in
recipients transplanted with Treg (P  .0005 on day 14, P  .0001
on day 40). T cell reconstitution, particularly CD4 cells, was
enhanced in the Treg group at both time points and reached
statistical signiﬁcance on day 40 (P  .003). The number of donor
natural killer cells was particularly increased on day 14 in the Treg
recipients (P  .0003). B-cell reconstitution was enhanced at day
40 in recipient animals that received Treg (P  .006). T cell
repertoire assessed by V-beta TCR screening with FACS analysis
showed a polyclonal distribution. To determine if the improved
and diverse lymphoid reconstitution is associated with increased
immune function, mice were challenged with murine CMV intra-
peritoneally at day 14. Two weeks after infection, 66% of animals
that received Treg in addition to Tcon, and 11% of animals that
received Tcon alone were alive (P  .05). Uninfected mice in the
respective groups served as controls to separate the effect of CMV
infection and GvHD on survival. Compared to infected animals,
no deaths were observed in the respective uninfected groups at this
time point (Tcon alone, P  .0004; Treg  Tcon, P  .21). In
both infected and control uninfected animals, Treg treated animals
had no evidence of signiﬁcant clinical GvHD compared to animals
that received Tcon alone. Decreased viral load and increased
CMV-speciﬁc T cell response in the Treg group conﬁrmed sur-
vival outcomes (P  .05). These ﬁndings indicate that Treg en-
hance both the quantitative and functional recovery of the lym-
phoid cell populations while providing protection against GvHD.
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Delayed immune reconstitution is a major cause of morbidity and
mortality after T cell depleted allogeneic progenitor cell transplant
(PCT). To accelerate immune reconstitution without GVHD, we
have administered escalating doses of L-leucyl-L-leucine methyl
ester (LLME) treated lymphocytes (DLI) to 18 patients post
CD34 cell-enriched PCT in an ongoing phase I trial. LLME’s
cellular toxicity occurs after polymerization by dipeptidyl pepti-
dase, leading to selective depletion of cells with cytotoxic effector
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